CURRENT NEWS & EVENTS

RevBio Receives ISO 13485 Certification for its Quality Management System!
MPWRM Resource Center and C-DOCTOR will be presenting at IADR 2023 in Bogota, Columbia!
GreenMark Biomedical Launches CrystLCare™ Biorestorative, Fluoride-Free!
GreenMark Biomedical’s LumiCare Carries Detection Rinse makes the cover of Dental Products Report!
Work led by MPWRM Resource Center Principal Investigator, Dr. David Mooney, and collaborators were featured in: CAR-T cell cancer immunotherapy gets personal
ITP PI, Dr. Pam Yelick (Tufts University), named fellow of the American Association for the Advancement of Science
GreenMark Biomedical Wins Competitive Startup Pitch Event at 2023 Yankee Dental Meeting
2023 5th Annual Stakeholders Summit: March 20-21, 2023
RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial
RevBio’s Novel Bone Adhesive to Fly on SpaceX CRS-26

OUR MISSION

Our mission is to strategically partner with scientists, engineers and clinicians to translate dental, oral and craniofacial tissue engineering and regenerative medicine technologies to the clinical marketplace. We assist by building a customized approach for success utilizing an innovative toolkit, access to an exclusive mentorship and an expansive community of translational resources.

LEARN MORE

NEW TRAINING RESOURCES

To view our latest training resources, click the link below.

TRAINING RESOURCES

LATEST HIGHLIGHTS

MRS TV features Resource Center

NEWS & EVENTS

Read about the latest news and developments.

NEWS
EVENTS

INTERDISCIPLINARY TRANSLATIONAL PROJECTS PROGRAM

The MPWRM Resource Center’s Interdisciplinary Translational Project (ITP) Program provides funding to support the clinical translation of promising technologies that address clear unmet needs with market potential in the dental, oral and craniofacial (DOC) space. The MPWRM Resource Center brings together a multi-disciplinary team of clinicans, engineers, scientists, and technology commercialization and regulatory experts to support the ITPs and to guide these technologies towards FDA submissions to achieve high impact clinical outcomes.